Additional file 8 of Targeting of a novel interplay between MET tyrosine kinase and NRF2 enhances sensitivity to Paclitaxel in triple negative breast cancer

Supplementary Material 8. Figure S8 A) Dose-response curves for PTX, PHA, DAS, ML-385 tested in PDO-21, PDO-43 and PDO-46. B) Table representing the calculation of the IC50 for each treatment in all PDOs. 4X digital magnification of bright-field images of organoids size of PDO-43 (C) and PDO-46 (D) cultures treated with PHA, DAS, ML-385 combined with PTX. Scale bar: 400 µm. E) Percentage of small, medium and large PDOs treated as in (C-D). F) Table representing the staining of MET and NRF2 in the 15 TNBC biopsies analysed by IHC. G) Representative examples of immunohistochemical staining of NRF2 and MET (20x). A and B: Case with negative MET and weak NRF2 expression. C and D: Case with moderate-to-weak MET staining and strong NRF2 expression. Results represent the mean of at least three independent experiments (± SEM). Statistical analysis: E) Two-way ANOVA followed by Tukey’s multiple comparison test (* respect to CTR, $ respect to inhibitors and # respect to PTX). PHA: PHA-665752, MET inhibitor. DAS: Dasatinib. ML-385: NRF2 inhibitor. PTX: Paclitaxel. ns: not significant; *, $, # p